CtrlK
TMO
NYSE
Life Sciences Tools & Services
$523.46
USD
-$2.77 (-0.53%)
At close: Jul 21, 2026, 4:00 PM EDT
Market Cap:
$192.09B
Volume:
3.5M
Previous Close
$526.23
Day Range
$495.04 - $526.38
52 Week Range
$403.36 - $643.99
Average Volume (10 Days)
1.6M
P/E Ratio (TTM)
28.06
Dividend Yield
0.34%
Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. The company is headquartered in Waltham, Massachusetts and currently employs 125,000 full-time employees. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. The company also provides purification and filtration technologies.
CEO
Mr. Marc Casper
Headquaters
Waltham, MASSACHUSETTS, US
Founded
1980
Employees
125,000
Thermo Fisher Scientific agreed to sell its microbiology business to private equity firm Astorg for approximately $1.075 billion. The unit, which generated $645 million in revenue in 2025, provides antimicrobial susceptibility testing and culture media solutions. The transaction is expected to close in the second half of 2026 and reflects the company's strategic shift toward higher-growth biopharma services.
0
0
Thermo Fisher reported first-quarter revenue of $11.01 billion and adjusted earnings per share of $5.44, both exceeding analyst expectations. However, organic revenue grew only 1%, missing estimates and signaling weakness in the company's core business. The company raised its full-year revenue guidance but investors focused on the underlying growth slowdown.
0
0
Thermo Fisher reported first-quarter results that exceeded Wall Street estimates, with revenue rising 6% to $11.01 billion and adjusted EPS of $5.44. Despite the beat and raised full-year guidance, the stock declined as investors focused on weak organic revenue growth of just 1% and ongoing headwinds in academic, government, and diagnostics markets.
0
0
Thermo Fisher reported first-quarter revenue of $11.01 billion and adjusted earnings per share of $5.44, both exceeding analyst expectations. However, organic revenue—which excludes acquisitions and currency effects—grew only 1% year-on-year, missing forecasts. The company raised its full-year revenue guidance to $47.3–$48.1 billion, reflecting contributions from its recent $9 billion Clario acquisition.
0
0
Thermo Fisher reported Q1 2026 revenue of $11.01 billion and adjusted EPS of $5.44, both beating analyst estimates. Despite raising full-year guidance and completing the $9 billion Clario acquisition, the stock declined as organic revenue growth of just 1% missed expectations, reflecting ongoing weakness in academic, government, and diagnostics markets.
0
0
A
Agilent Technologies Inc
$132.86
+2.0%
WAT
Waters Corp
$367.55
+2.8%
